Hepion pharmaceuticals, inc. announces termination of merger agreement with pharma two b ltd.

Edison, n.j., dec. 11, 2024 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq: hepa) (the “company” or “hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, today announced that it has entered into a termination agreement with pharma two b ltd. which terminates the merger agreement between the two parties that was previously entered into on july 19, 2024.
HEPA Ratings Summary
HEPA Quant Ranking